Product Liability Update - February 2014
Drug and Device Manufacturers Beware: Comments Could Result in FDA Troubles
by Amanda Sheridan
After appearing on CNBC television show Fast Money, the CEO of Aegerion Pharmaceuticals received a warning letter from the United States Food and Drug Administration (FDA) Office of Prescription Drug Promotion. The agency asserted that comments made on the show constituted promotional speech and resulted in Aegerion’s cholesterol lowering drug, Juxtapid, being misbranded.